JDRF funding opportunities

We offer a wide range of funding schemes for qualified researchers in the field of type 1 diabetes and its associated complications.

The following JDRF funding opportunities are administered by our central office in New York. Applications must be submitted via RMS360, the JDRF Grant Management System. This page provides applicants with guidelines for application submission.

Please follow the links below to find out more about these opportunities.

Targeted schemes

Cures
Improving Risk Prediction for T1D Onset: Modelling and Assay Development for Clinical and Commercial Use
Multiple studies in both high-risk family members and the general population have demonstrated that screening for the risk of T1D followed by appropriate metabolic monitoring can dramatically reduce the rates of diabetic ketoacidosis (DKA) at diagnosis, which has been correlated with improvements in both near and long-term glucose control and health outcomes. However, these programs still exist within the research setting and are not yet suitable to be integrated into the real-world health care setting. This RFA calls for projects that will aid the translation of risk assessment tools for T1D into clinical use. The specific focus of this call is for the improvements of existing genetics and autoantibody risk assessment tools and their integration into clinically and commercially utilized testing platforms.
Letter of Intent Deadline: 15 December 2021
Notification of Full Application Request: 12 January 2022
Full Application Deadline (on invite only): 16 February 2022
Response to Applicants: 30 June 2022
Earliest anticipated start date: 31 August 2022

Novel Immune Strategies to Enhance Beta Cell Replacement Therapies for T1D
Despite significant progress in the development of alternative renewable sources of insulin producing cells to overcome the shortage of donor tissue, major scientific and technical challenges in overcoming recurring autoimmunity and allogeneic immune rejection remain which must be addressed before beta cell replacement can be widely implemented as a cure for established T1D. The reliance on systemic administration of immunosuppressive drugs to protect the cell graft from the recipient’s immune response is one key limitation which calls for the development of safer and better alternatives capable of ensuring long-term graft survival and function.
Letter of Intent Deadline was 25 October 2021
Notification of Full Application Request: 8 November 2021
Full Application Deadline (on invite only): 20 December 2021
Response to Applicants: 30 April 2022
Earliest anticipated start date: 31 July 2022

Developing Combination Therapies in Type 1 Diabetes
T1D is a complex disease, suggesting that multipronged therapeutic approaches might be needed to improve clinical outcomes. To that end, proposals are sought for preclinical and/or clinical studies with novel approaches toward the development of combination therapies which utilize multiple therapeutic agents targeting mechanisms involved in the following biological pathways: immune modulation (including antigen specific targeting), beta cell function and regeneration/replication, and/or metabolic control. Proposals will be considered that combine agents with different modes of action and targets, such as those that modulate immune responses, improve metabolic status, and/or improve/protect beta cell function.
Letter of Intent Deadline was 17 November 2021
Notification of Full Application Request: 15 December 2021
Full Application Deadline (on invite only): 31 January 2022
Response to Applicants: 31 May 2022
Earliest anticipated start date: 31 July 2022

Improving Lives
Novel Approaches to Address Disordered Eating and Eating Disorders in Type 1 Diabetes
People with T1D have a 2-3 fold higher risk of developing eating disorders than their peers without diabetes, and a significant number of people with T1D have disordered eating behaviors but do not meet full diagnostic criteria for ED. Early detection and targeted prevention strategies could reduce the likelihood of development of a clinical ED. To develop effective approaches to prevention and early intervention models, increased knowledge of the etiology of DEB and ED is needed.
Letter of Intent Deadline was 27 October 2021
Notification of Full Application Request: 3 November 2021
Full Application Deadline (on invite only): 6 December 2021
Response to Applicants: 30 April 2022
Earliest anticipated start date: 30 June 2022

– Clinical Trials to Advance Therapies for Nephropathy and Cardiovascular Disease in Type 1 Diabetes
Despite advanced technologies to maintain glucose control, long-term complications such as diabetic nephropathy (DN) and cardiovascular disease (CVD) are still the primary cause of morbidity and mortality in people with T1D. There is currently a lack of targeted therapies for DN or CVD approved for use by people with T1D, in part because people with T1D are seldom included in drug trials for these diabetic complications. To fill this gap, JDRF invites applications for clinical trials to advance therapies to improve DN and/or CVD outcomes in T1D.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Letter of Intent Deadline was 8 November 2021
Notification of Full Application Request: 22 November 2021
Full Application Deadline (on invite only): 5 January 2022
Response to Applicants: 31 May 2022
Earliest anticipated start date: 31 August 2022

– Development of CGMs with Continuous Ketone Monitoring Functionality for DKA Prevention in T1D
Diabetic ketoacidosis (DKA) is a dangerous acute complication of T1D that is insufficiently addressed or even sometimes exacerbated by current therapeutic options. To fill this gap, JDRF invites applications to develop continuous ketone monitor (CKM) functionality in continuous glucose monitor (CGM) devices to warn users of impending DKA events and allow preventive actions to be taken.
Letter of Intent (LOI)’s can be submitted to JDRF’s Strategic Research Agreement (SRA) or Industry Discovery and Development Program (IDDP) grant mechanisms.
Full Application Deadline (on invite only) was 30 September 2021
Response to Applicants: March 2022
Earliest anticipated start date: May 2022

Training funding schemes

These funding sources are typically available annually

Postdoctoral Fellowships
– Open to those at a relatively early stage of their career.
– PhD, MD, DMD, DVM, or equivalent received no more than five years before the application is submitted. Must not be simultaneously serving an internship or residency.
– Up to  $57,984 to $69,060 per year, for up to 3 years.
– The application deadline was Tuesday 29 June 2021.
Funding notification: 31 January 2022.
– Earliest start: 31 March 2022

Advanced Postdoctoral Fellowships
– Open to those who have completed some postdoctoral training, show extraordinary promise and are preparing for a transition to an independent research position.
– PhD, MD, DMD, DVM, or equivalent received no more than six years before the application is submitted. Must not be simultaneously serving an internship or residency.
– Up to $95,000 per year, for up to 3 years.
– The application deadline was Tuesday 29 June 2021.
Funding notification: 31 January 2022.
– Earliest start: 31 March 2022

Career Development Awards
– Open to individuals at an early stage of their independent academic career.
– PhD, MD, DMD, DVM, or equivalent and in an academic faculty-level position since less than 3 years before the submission date.
– Up to $150,000 per year, for up to 5 years.
– The application deadline was Wednesday 22 September 2021.
Funding notification: 30 April 2022.
– Earliest start: 1 July 2022.

Early Career Patient-Orientated Diabetes Research Awards
– Open to clinical researchers at a relatively early stage of their independent career.
– MD or MR-PhD and in their first faculty-level appointment less than 5 years before the submission date.
– Up to $150,000 per year, for up to 5 years.
– The application deadline was Wednesday 22 September 2021.
– Funding notification: 30 April 2022.
– Earliest start: 1 July 2022.

JDRF International Diabetes Psychology Fellowship Program
– The fellowship is intended for those at a relatively early stage of their career.
– PhD, PsyD, DClinPsy, MD or equivalent from an accredited institution gained no more than 5 years prior application submission
– Not be simultaneously serving an internship or residency.
– Up to $65,000 per year, for up to 2 years
– The application deadline was Tuesday 9 November 2021.
Funding notification: February 2022.
– Earliest start: 1 April 2022.
Note: In line with other JDRF fellowships, applicants may be eligible for a JDRF UK Postdoctoral Fellowship Research Communication Stipend.

Ongoing funding schemes

Project Concepts for Strategic Research Agreements
– Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research.
– PhD, MD, DMD, DVM, or equivalent and in a faculty position or equivalent.
– Project concept Letter of Intent deadlines: Tuesday 3 May 2022
Notification for the following opportunity will be 17 June 2022

– Successful Project Concept applicants will be contacted for further project development by JDRF personnel.
– Letter of Intent status notification for applications received by Tuesday 2 November 2021: 17 December 2021

Innovative Grants
– Funding for highly innovative research proposals with significant potential to accelerate JDRF’s mission.
– PhD, MD, DMD, DVM, or equivalent and in a faculty position or equivalent.
– Up to $110,000 per year, for up to 1 year.
– The application deadline was Thursday 14 October 2021.
Funding notification: 31 January 2022.
– Earliest start: 1 March 2022.

Other funding schemes

Industry Discovery & Development Partnerships
– Aimed to promote for-profit interest in JDRF’s mission to find a cure for type 1 diabetes and its complications.
– Biotechnology/ pharmaceutical companies or other for-profit entities, either publicly or privately held.
– JDRF also encourages Partnership applications from companies proposing collaboration with academic researchers.
– Discovery Partnerships: 2 year contract – Up to $250K/yr/2
– Contact the appropriate Therapeutic Area Program Director.

Conference Grants
– Supports scientific meetings, conferences, and workshops relevant to JDRF mission.
– Does not provide individual support to an applicant for conference attendance.
– Applications are accepted for consideration throughout the year. They should be submitted to the appropriate Scientific Program Staff 3-6 months prior to the meeting date.